Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Fate Therapeutics (FATE – Research Report), Danaher (DHR – Research Report) and Roche Holding AG (RHHVF – Research Report).
Fate Therapeutics (FATE)
Barclays analyst Peter Lawson assigned a Buy rating to Fate Therapeutics today and set a price target of $10.00. The company’s shares closed last Tuesday at $4.54.
According to TipRanks.com, Lawson is a 4-star analyst with an average return of
Fate Therapeutics has an analyst consensus of Hold, with a price target consensus of $7.27.
See Insiders’ Hot Stocks on TipRanks >>
Danaher (DHR)
Barclays analyst Luke Sergott maintained a Hold rating on Danaher today and set a price target of $270.00. The company’s shares closed last Tuesday at $253.11.
According to TipRanks.com, Sergott has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on Danaher is a Strong Buy with an average price target of $272.14, a 6.8% upside from current levels. In a report released yesterday, Bank of America Securities also maintained a Hold rating on the stock with a $258.00 price target.
Roche Holding AG (RHHVF)
J.P. Morgan analyst Richard Vosser maintained a Sell rating on Roche Holding AG today and set a price target of CHF210.00. The company’s shares closed last Tuesday at $250.79, close to its 52-week low of $236.98.
According to TipRanks.com, Vosser is a 4-star analyst with an average return of
Currently, the analyst consensus on Roche Holding AG is a Hold with an average price target of $270.84, representing a 9.1% upside. In a report issued on April 16, Morgan Stanley also maintained a Sell rating on the stock with a CHF260.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on FATE:
- Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
- Fate Therapeutics files to sell 3.64M shares of common stock for holders
- Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
- Fate Therapeutics price target raised to $6 from $2 at BofA
- Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
